Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab-Based Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Joo-Hwan | - |
dc.contributor.author | Yeo, Ja Hyun | - |
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Lee, Woon-Ki | - |
dc.contributor.author | Yang, Jun-Young | - |
dc.contributor.author | Kim, Hyung-Sik | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.date.accessioned | 2021-07-04T05:41:16Z | - |
dc.date.available | 2021-07-04T05:41:16Z | - |
dc.date.created | 2021-05-20 | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81526 | - |
dc.description.abstract | Objectives: Trastuzumab is used as an agent against human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). The aim of this study was to determine how HER2 gene amplification and neutrophil-to-lymphocyte ratio (NLR) could predict long-term survival in AGC patients that underwent trastuzumab-based chemotherapy. Methods: We retrospectively reviewed medical records of 112 patients between 28 and 91 years old (median of 66 y) with AGC treated with first-line trastuzumab-based chemotherapy. The level of HER2 gene amplification was determined by the HER2/centromere enumerator probe 17 (CEP17) ratio and HER2 gene copy number (GCN). NLR was calculated as the neutrophil count divided by the lymphocyte counts. Results: Median HER2/CEP17 ratio, HER2 GCN, and NLR values were 2.85, 7.1, and 2.81, respectively. Objective response rate in both high HER2/CEP17 ratio (59.4% vs. 28.1%, P=0.012) and HER2 GCN groups (62.1% vs. 33.3%, P=0.032) was higher than that of each group. High NLR correlated with significantly worse median overall survival (OS) (median OS, 8.2 vs. 18.9 mo, P=0.002) and progression free survival (PFS) (median PFS: 5.1 vs. 8.0 mo, P=0.005). However, median OS and PFS were not significantly different according to HER2/CEP17 ratio or HER2 GCN. In the multivariate analysis, high NLR, Eastern Cooperative Group performance status, and poorly differentiated/signet ring cell type were independent factors for OS. Conclusions: NLR was a significant predictor of long-term survival in AGC patients treated with first-line trastuzumab-based chemotherapy. Future validation of prospective trials with larger patient populations will be needed. © 2021 Lippincott Williams and Wilkins. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.title | Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab-Based Chemotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000656195500002 | - |
dc.identifier.doi | 10.1097/COC.0000000000000810 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, v.44, no.6, pp.232 - 238 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85105567254 | - |
dc.citation.endPage | 238 | - |
dc.citation.startPage | 232 | - |
dc.citation.title | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.citation.volume | 44 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Park, Joo-Hwan | - |
dc.contributor.affiliatedAuthor | Yeo, Ja Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.contributor.affiliatedAuthor | Lee, Woon-Ki | - |
dc.contributor.affiliatedAuthor | Yang, Jun-Young | - |
dc.contributor.affiliatedAuthor | Kim, Hyung-Sik | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.type.docType | Article in Press | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | HER2 gene amplification | - |
dc.subject.keywordAuthor | neutrophil-to-lymphocyte ratio | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | trastuzumab | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.